FDA, OpenAI in Talks on AI Drug Review Amid Oversight Concerns

OpenAI has engaged in discussions with the U. S. Food and Drug Administration (FDA) regarding the agency’s efforts to expand its use of artificial intelligence (AI) to accelerate drug evaluations, amid broader plans to integrate AI more widely across its centers. OpenAI and the U source: https://news.shib.io/2025/05/15/fda-openai-in-talks-on-ai-drug-review-amid-oversight-concerns/?utm_source=rss&utm_medium=rss&utm_campaign=fda-openai-in-talks-on-ai-drug-review-amid-oversight-concerns